Seminars in NeurologyPub Date : 2026-10-01Epub Date: 2026-05-25DOI: 10.1055/a-2870-2333
Sanjay Pandey, Aasef G Shaikh
{"title":"Tremor.","authors":"Sanjay Pandey, Aasef G Shaikh","doi":"10.1055/a-2870-2333","DOIUrl":"10.1055/a-2870-2333","url":null,"abstract":"","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":"414"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148018478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seminars in NeurologyPub Date : 2026-10-01Epub Date: 2026-02-06DOI: 10.1055/a-2789-0097
TinaMarie Lieu, Rich Able, Ian Smith, Sheng-Han Kuo
{"title":"Essential Tremor Pharmacotherapy: Bench to Bedside.","authors":"TinaMarie Lieu, Rich Able, Ian Smith, Sheng-Han Kuo","doi":"10.1055/a-2789-0097","DOIUrl":"10.1055/a-2789-0097","url":null,"abstract":"<p><strong>Abstract: </strong>Essential tremor (ET) is among the most common movement disorders, yet pharmacologic options remain limited. Recent mechanistic insights implicate abnormal cerebello-thalamo-cortical oscillations arising from impaired GABAergic inhibition, T-type calcium channel-driven rhythmicity, and SK/AMPA receptor-mediated hyperexcitability. Translational studies have explored neuroactive steroids targeting extrasynaptic GABA<sub>A</sub> receptors, T-type calcium channel blockers, SK-channel enhancers, and AMPA antagonists, with variable clinical efficacy. These findings highlight the biological heterogeneity of ET and the challenge of aligning molecular targets with meaningful clinical outcomes. Future progress will require precision-based pharmacotherapy, integrating circuit-specific biomarkers, mechanistic patient stratification, and real-world measures of tremor impact to transform the landscape of ET treatment.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":"532-543"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seminars in NeurologyPub Date : 2026-10-01Epub Date: 2025-12-11DOI: 10.1055/a-2769-6567
Nutan Sharma
{"title":"Tremors in Children.","authors":"Nutan Sharma","doi":"10.1055/a-2769-6567","DOIUrl":"10.1055/a-2769-6567","url":null,"abstract":"<p><strong>Abstract: </strong>Tremor is a hyperkinetic movement disorder that consists of rhythmic, involuntary oscillatory movement of a body part. It may be present at birth or develop later during childhood. Pediatric tremor may be an isolated disorder or a sign of an underlying genetic and/or neurologic disease. This review provides a summary of the features and classification of pediatric tremors, recommended clinical evaluation, and currently available treatments.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":"485-491"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seminars in NeurologyPub Date : 2026-10-01Epub Date: 2026-05-07DOI: 10.1055/a-2870-6059
Aparna Wagle Shukla, Pattamon Panyakaew
{"title":"Neurophysiological Basis of Tremor Disorders: Parkinson's Disease, Essential Tremor, Tremor in Dystonia, and Holmes Tremor.","authors":"Aparna Wagle Shukla, Pattamon Panyakaew","doi":"10.1055/a-2870-6059","DOIUrl":"10.1055/a-2870-6059","url":null,"abstract":"<p><strong>Abstract: </strong>Tremor disorders encompass heterogeneous syndromes with distinct clinical, electrophysiological, and pathophysiological characteristics. Parkinson's disease tremor typically presents as a unilateral 4 to 6 Hz rest tremor, with re-emergent postural components or pure postural in some, driven by abnormal pallido-thalamo-cortical (PTC) oscillations and modulated by cerebellar inputs. Essential tremor is characterized by bilateral 4 to 8 Hz kinetic >postural tremor with regular, rhythmic EMG bursts, reflecting dysfunction within the cerebello-thalamo-cortical (CTC) pathway. Tremor in dystonia is frequently unilateral, irregular, and position- or task-specific, 3 to 5 Hz oscillations superimposed on dystonic co-contractions; the rhythmic component arises from CTC disturbances, while jerky dystonia involves PTC abnormalities. Holmes tremor is a slow (2.5-5 Hz) proximal tremor combining rest, postural, and kinetic features, resulting from multiple brain substrates in globus pallidus internus, red nucleus, and/or cerebellum (PTC and CTC). Understanding the underlying circuitry (or network) dysfunctions which are convergent as well as divergent across tremor syndromes can improve diagnostic accuracy and guide individualized therapeutic strategies.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":"509-520"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13297120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147845187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seminars in NeurologyPub Date : 2026-10-01Epub Date: 2026-06-01DOI: 10.1055/a-2848-9343
Lucie Ahn, Ibada I Chowdhary, Aasef G Shaikh
{"title":"Pendular Nystagmus and Oculopalatal Tremor.","authors":"Lucie Ahn, Ibada I Chowdhary, Aasef G Shaikh","doi":"10.1055/a-2848-9343","DOIUrl":"10.1055/a-2848-9343","url":null,"abstract":"<p><strong>Abstract: </strong>Acquired pendular nystagmus consists of quasi-sinusoidal oscillations of the eyes that significantly impair gaze stability and visual clarity. It most commonly occurs in demyelinating disorders such as multiple sclerosis and in acquired degenerative conditions like oculopalatal tremor. Other etiologies-including drug toxicity, metabolic and genetic disorders, and granulomatous diseases-can also produce syndromes featuring pendular nystagmus. Analysis of its kinematic properties has provided clues to the underlying mechanisms of this otherwise enigmatic disorder. In this review, we examine the clinical features of neurological conditions associated with pendular nystagmus, with emphasis on its acquired forms, and summarize recent advances in diagnostic strategies and therapeutic development. Pendular nystagmus is defined by quasi-sinusoidal oscillations of the eyes that impair visual acuity and produce oscillopsia.1 Despite its designation as \"nystagmus,\" this disorder lacks the hallmark waveform of classical nystagmus-slow drifts followed by rapid corrective saccades. Instead, pendular nystagmus consists of consecutive slow phases of eye movement, giving it a pendular appearance. These oscillations typically exhibit a dominant frequency of 4 to 6 Hz, although certain conditions, such as oculopalatal tremor (OPT; see below), present with lower frequencies around 2 Hz, while demyelinating disorders may reach frequencies up to 8 Hz. The phenomenology of pendular nystagmus reflects diverse underlying pathophysiological mechanisms associated with neurodegenerative, toxic-metabolic, immune-mediated, and genetic disorders. This review aims to provide a comprehensive resource on the pathophysiology, phenomenology, etiology, and therapy of pendular nystagmus.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":"453-464"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148145343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Seminars in NeurologyPub Date : 2026-10-01Epub Date: 2025-12-15DOI: 10.1055/a-2769-7282
Kartika Gulati, Sanjay Pandey
{"title":"Functional Tremor.","authors":"Kartika Gulati, Sanjay Pandey","doi":"10.1055/a-2769-7282","DOIUrl":"10.1055/a-2769-7282","url":null,"abstract":"<p><strong>Abstract: </strong>Functional tremor (FT) is the most prevalent subtype of functional movement disorders, characterized by variability, distractibility, and entrainability on clinical examination. Diagnosis relies on positive clinical and electrophysiological signs, shifting emphasis from a diagnosis of exclusion to \"rule-in\" criteria. Surface electromyography and tremor analysis are essential tools in establishing the diagnosis. Pathophysiology involves abnormal motor co-activation, disrupted volitional awareness, and impaired predictive processing, resulting in tremor perceived as involuntary despite intact motor pathways. Management requires a multidisciplinary approach, including physiotherapy, occupational therapy, cognitive-behavioral interventions, biofeedback, and transcranial magnetic stimulation. FT often results in persistent disability, with limited treatment response. Management is hindered by diagnostic challenges, especially in functional overlay, limited training, cultural misconceptions, and underutilization of neurophysiological and rehabilitation interventions. Improving clinician training, expanding access to neurophysiology, and multidisciplinary care, along with high-quality prospective specific research and standardized care pathways, is essential to optimize outcomes.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":"492-501"},"PeriodicalIF":2.2,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145764068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Syndromes of Peripheral Nervous System Neurotoxicity from Immune-Checkpoint Inhibitors.","authors":"Isaac Smith, Minna Choi, Sakinah Sabadia","doi":"10.1055/a-2936-5945","DOIUrl":"https://doi.org/10.1055/a-2936-5945","url":null,"abstract":"<p><strong>Abstract: </strong>The introduction of immune checkpoint inhibitors (ICIs) has dramatically changed the landscape of treatment for a variety of cancers. However, there is increasing recognition of neurotoxicity related to ICI use. In this review, we will discuss the peripheral nervous system neurologic immune related adverse events (PNS-nirAEs) of anti-CTLA4, anti-PD1, and anti-PDL1 ICIs, including nerve, neuromuscular junction, muscle, and overlap syndromes. We will discuss the relevant epidemiology, pathophysiology, clinical syndromes, diagnostic approaches, treatment, and prognosis of PNS-nirAEs. We will discuss the safety and efficacy of ICIs when utilized in patients with pre-existing neurologic autoimmune disorders (NAIDs). Lastly, we will discuss relevant treatment options and when to consider rechallenging with ICI after an initial de novo PNS-nirAE or exacerbation of a pre-existing NAID.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148851862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra Balshi, Prashanth Rajarajan, Caleb R S McEntire, Giovanna S Manzano
{"title":"Neurologic Complications of Cancer Immunotherapy.","authors":"Alexandra Balshi, Prashanth Rajarajan, Caleb R S McEntire, Giovanna S Manzano","doi":"10.1055/a-2936-4931","DOIUrl":"https://doi.org/10.1055/a-2936-4931","url":null,"abstract":"<p><strong>Abstract: </strong>The use of oncologic-directed immunotherapies, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T cell (CAR-T) therapy, has risen exponentially in recent years. Although these therapies have been shown to improve long-term survival and quality of life in responsive patients, their nonspecific immune system activation can lead to unanticipated neurotoxicity, among other complications. Immune-related adverse events (irAEs) may involve any location in the entire neuroaxis, posing a diagnostic challenge, and may cause severe, life-threatening complications. ICI-related neurotoxicities may include peripheral neuropathies, myositis, myasthenia gravis, encephalitis, aseptic meningitis, myelitis, and demyelinating disorders. CAR-T therapies carry a comparatively higher risk of neurologic irAEs, most notably immune effector cell-associated neurotoxicity syndrome. In this review, neurotoxicity syndromes associated with ICI and CAR-T therapies are outlined, along with diagnostic approaches and management strategies.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148834323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Equity in Neurotoxicity Care in the Era of Cancer Immunotherapy.","authors":"Rosalina Magalhaes Pereira, Joshua A Budhu","doi":"10.1055/a-2936-3979","DOIUrl":"10.1055/a-2936-3979","url":null,"abstract":"<p><strong>Abstract: </strong>Immunotherapies such as chimeric antigen receptor T cell (CAR-T) therapy and immune checkpoint inhibitors have improved cancer survival but are associated with potentially severe neurotoxicities that can impair neurologic function, quality of life, and survival. Despite their growing use, substantial disparities persist in the recognition, diagnosis, and management of cancer therapy-related neurotoxicities, disproportionately affecting underserved populations. In this review, we apply the social-ecological model (SEM) to examine how factors across individual, interpersonal, organizational, community, and policy levels contribute to inequities in neurotoxicology care. We synthesize evidence on barriers to early detection and access to neurologic expertise and highlight emerging strategies to promote equity, including early symptom recognition, improved specialty access, and supportive institutional infrastructure. We also explore the potential of behavioral economics-informed approaches and artificial intelligence-enabled tools, including telemedicine and remote monitoring, as scalable strategies to reduce inequities in neurotoxicity care.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13537097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148725841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdulaziz Al-Abdulghani, Andrew Dugue, Scott N Grossman, Doria M Gold
{"title":"Neuro-Ophthalmic Manifestations of Immunotherapy Toxicity.","authors":"Abdulaziz Al-Abdulghani, Andrew Dugue, Scott N Grossman, Doria M Gold","doi":"10.1055/a-2928-7527","DOIUrl":"10.1055/a-2928-7527","url":null,"abstract":"<p><strong>Abstract: </strong>Approximately half of the brain subsumes visual function, so neurologic toxicities of immunotherapy medications may frequently manifest with visual symptoms. As the use of immunotherapeutic medicines proliferates for a broader array of indications, neuro-ophthalmologists in clinical practice may increasingly be referred patients with visual symptoms that result. In this review, we discuss the spectrum of neuro-ophthalmic manifestations of immunotherapy toxicity with a broad review of the literature. Both immune checkpoint inhibitors and chimeric antigen receptor T cell therapies are discussed.</p>","PeriodicalId":49544,"journal":{"name":"Seminars in Neurology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148671130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}